{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T23:12:51Z","timestamp":1781565171885,"version":"3.54.5"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009702","name":"Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009702","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.dld.2025.04.025","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T15:34:21Z","timestamp":1746545661000},"page":"1419-1427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3482-0109","authenticated-orcid":false,"given":"D.","family":"Noviello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-7478","authenticated-orcid":false,"given":"W.","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.S.","family":"Conforti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bezzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1099-442X","authenticated-orcid":false,"given":"F.","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Fantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3187-2894","authenticated-orcid":false,"given":"E.V.","family":"Savarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4635-3050","authenticated-orcid":false,"given":"S.","family":"Festa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9421-3087","authenticated-orcid":false,"given":"D.G.","family":"Ribaldone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4654-0865","authenticated-orcid":false,"given":"L.","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Vigan\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-6832","authenticated-orcid":false,"given":"N.","family":"Imperatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6480-5778","authenticated-orcid":false,"given":"L.","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M. Carvalhas","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Scardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-2534","authenticated-orcid":false,"given":"S.","family":"Saibeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4446-6262","authenticated-orcid":false,"given":"P.","family":"Balestrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4702-3539","authenticated-orcid":false,"given":"M.","family":"Campigotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-0115","authenticated-orcid":false,"given":"A.G.","family":"Gravina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0871-4644","authenticated-orcid":false,"given":"R.","family":"Spagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8334-7541","authenticated-orcid":false,"given":"F.","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0803-7903","authenticated-orcid":false,"given":"B.","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Di","family":"Sario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-1923","authenticated-orcid":false,"given":"M.","family":"Baldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Di","family":"Mitri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4757-9834","authenticated-orcid":false,"given":"E.","family":"Tettoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4004-0150","authenticated-orcid":false,"given":"S.","family":"Calderone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1572-0118","authenticated-orcid":false,"given":"A.","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5128-3846","authenticated-orcid":false,"given":"F.S.","family":"Macaluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3469-4720","authenticated-orcid":false,"given":"M.","family":"Ventimiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8077-8175","authenticated-orcid":false,"given":"F.","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De Francesco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Piazza O","family":"Sed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Marcozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.D.","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Onali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"De Barba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Orr\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Laffusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2025.04.025_bib0001","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2025.04.025_bib0002","first-page":"4","article-title":"Real-world treatment patterns and physician preferences for biologics in moderate-to-severe inflammatory bowel disease: retrospective chart review in Europe","volume":"360","author":"Huynh","year":"2022","journal-title":"Crohns Colitis"},{"key":"10.1016\/j.dld.2025.04.025_bib0003","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.cgh.2020.01.008","article-title":"First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.04.025_bib0004","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.cgh.2022.04.038","article-title":"Superior effectiveness of Tofacitinib compared to Vedolizumab in Anti-TNF-experienced ulcerative colitis patients: a nationwide Dutch registry study","volume":"21","author":"Straatmijer","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.04.025_bib0005","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.04.025_bib0006","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.dld.2025.04.025_bib0007","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.dld.2025.04.025_bib0008","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.dld.2025.04.025_bib0009","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.dld.2025.04.025_bib0010","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00535-018-1480-0","article-title":"Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease","volume":"53","author":"Schreiber","year":"2018","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2025.04.025_bib0011","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.dld.2021.04.018","article-title":"Effectiveness and safety of tofacitinib for the treatment of ulcerative colitis: a single-arm meta-analysis of observational studies","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.04.025_bib0012","series-title":"Statistical methods for rates and proportions","author":"Fleiss","year":"2013"},{"key":"10.1016\/j.dld.2025.04.025_bib0013","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.chest.2020.03.010","article-title":"Sample size estimation in clinical research: from randomized controlled trials to observational studies","volume":"158","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.dld.2025.04.025_bib0014","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ibd\/izad115","article-title":"Real-world evidence comparing Tofacitinib and Vedolizumab in anti-TNF-experienced patients with ulcerative colitis","volume":"30","author":"Adimadhyam","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.04.025_bib0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/apt.17570","article-title":"Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: a propensity-matched cohort study","volume":"58","author":"Kochhar","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.04.025_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101866","article-title":"Comparative onset of effect of biologics and small molecules in moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis","volume":"57","author":"Attauabi","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.dld.2025.04.025_bib0017","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of Tofacitinib for moderate to severe ulcerative colitis: a Multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.04.025_bib0018","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.cgh.2023.10.029","article-title":"ENTERPRET: a randomized controlled trial of Vedolizumab dose optimization in patients with ulcerative colitis who have early nonresponse","volume":"22","author":"Jairath","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2025.04.025_bib0019","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/ibd\/izad115","article-title":"Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis","volume":"30","author":"Adimadhyam","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.dld.2025.04.025_bib0020","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/apt.18006","article-title":"Meta-analysis: persistence of advanced therapies in the treatment of inflammatory bowel disease","volume":"59","author":"Yiu","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2025.04.025_bib0021","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.04.025_bib0022","first-page":"jjae151","article-title":"Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease","author":"Samnani","year":"2024","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.dld.2025.04.025_bib0023","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.dld.2022.01.127","article-title":"Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD clinical guidelines based on the GRADE methodology","volume":"54","author":"Macaluso","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.dld.2025.04.025_bib0024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2019.04.059","article-title":"Tofacitinib treatment is associated with modest and reversible increases in serum lipids in patients with ulcerative colitis","volume":"18","author":"Sands","year":"2020","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865825007352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:27:51Z","timestamp":1762554471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865825007352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1590865825007352"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.025","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-life effectiveness and safety of tofacitinib and vedolizumab as 2nd-line for ulcerative colitis after anti-TNFs: A multicenter cohort IGIBD study (VE2TO-UC)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2025.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}